Sugi Predict

Sugi Predict / Compounds / SCHEMBL832933

SCHEMBL832933

SCHEMBL832933

O=C(O)CC1CC=CC2c3ccccc3NC12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN7 P35236 8/20 0.54
▸ HSPA1A P0DMV8 6/20 0.54
▸ TDP1 Q9NUW8 4/20 0.54
▸ EGFR P00533 1/20 0.43
▸ MAPT P10636 5/20 0.40
▸ MEN1 O00255 5/20 0.40
▸ KMT2A Q03164 5/20 0.40
▸ L3MBTL1 Q9Y468 4/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ ALOX15 P16050 3/20 0.40
▸ HSD17B10 Q99714 3/20 0.40
▸ GAA P10253 3/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ HPGD P15428 3/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ MCL1 Q07820 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ GAPDH P04406 5/20 0.39
▸ POLB P06746 4/20 0.39
▸ BLM P54132 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1200754 0.77 HSPA1A (0.43) PTPN7HSPA1ATDP1MAPTMEN1
SCHEMBL10924726 0.75 PTPN7 (0.52) PTPN7HSPA1ATDP1MAPTMEN1
SCHEMBL7892118 0.75 PTPN7 (0.53) PTPN7HSPA1ATDP1MAPTMEN1
SCHEMBL6245088 0.72 HSPA1A (0.49) PTPN7HSPA1ATDP1MAPTMEN1
SCHEMBL1877920 0.72 PTPN7 (0.49) PTPN7HSPA1ATDP1MAPTMEN1
SCHEMBL10877400 0.71 HSPA1A (0.49) PTPN7HSPA1ATDP1MAPTMEN1
SCHEMBL31492743 0.70 PTPN7 (1.00) PTPN7HSPA1ATDP1MAPTMEN1
SCHEMBL26098723 0.70 PTPN7 (1.00) PTPN7HSPA1ATDP1MAPTMEN1
SCHEMBL1879259 0.69 MAPT (0.47) PTPN7HSPA1ATDP1MAPTMEN1
SCHEMBL6678349 0.68 PTPN7 (0.65) PTPN7HSPA1ATDP1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2558447-B1 3-(HETEROARYL-AMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2014-09-17 — — EP disclosed
US-8697869-B2 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2014-04-15 — — US disclosed
US-20130065902-A1 3-(HETEROARYL-AMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-03-14 — — US disclosed
EP-2558447-A1 3-(HETEROARYL-AMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-02-20 — — EP disclosed
US-8143304-B2 (3-amino-1,2,3,4-tetrahydro-9 H-carbazol-9-yl)-acetic acid derivatives ACTELION PHARMACEUTICAL LTD. (CH) 2012-03-27 — — US disclosed
EP-2051962-B1 (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2011-10-26 — — EP disclosed
WO-2011117798-A1 3-(HETEROARYL-AMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2011-09-29 — — WO disclosed
EP-2316824-A1 (3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates Actelion Pharmaceuticals Ltd. (CH) 2011-05-04 — — EP disclosed
US-20100190830-A1 (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2010-07-29 — — US disclosed
EP-2051962-A1 (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-04-29 — — EP disclosed
WO-2001079169-A2 PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS MERCK FROSST CANADA & CO. (CA) 2001-10-25 — — WO disclosed
EP-0200391-B1 SUBSTITUTED 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-1-ACETIC ACID DERIVATIVES AMERICAN HOME PRODUCTS CORPORATION (US) 1989-08-09 — — EP disclosed
US-4709048-A ALKYLATION, HYDROLYSIS, CYCLIZATION AMERICAN HOME PRODUCTS CORP. (US) 1987-11-24 — — US disclosed
US-4701533-A ANALGESICS AND ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1987-10-20 — — US disclosed
US-4687860-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1987-08-18 — — US disclosed
EP-0200391-A2 Substituted 2,3,4,9-tetrahydro-1H-carbazole-1-acetic acid derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1986-11-05 — — EP disclosed
US-4616028-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1986-10-07 — — US disclosed
US-4584312-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1986-04-22 — — US disclosed
US-4578398-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1986-03-25 — — US disclosed
US-4057559-A ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1977-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190830-A1 (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives PTGDR, PTGER1, PTGIR PTPN7 4338/4885HSPA1A 2775/4885TDP1 3588/4885
US-20130065902-A1 3-(HETEROARYL-AMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGDR, PTGER1, PTGDR2 PTPN7 4508/4885HSPA1A 2475/4885TDP1 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.